ArticleJournal of Korean Neurosurgical Society2026
The Utility of Antiplatelet Assay-Guided Individualized Dual Antiplatelet Therapy in Carotid Artery Stenting for Unstable Plaques.
Article in Journal of Korean Neurosurgical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of individualized dual antiplatelet therapy (DAPT) using VerifyNow in reducing periprocedural ischemic complications following carotid artery stenting (CAS), particularly in patients with unstable plaques.
methodsThis retrospective, single-center study included 187 patients who underwent elective CAS between January 2018 and September 2024. Patients were divided into two groups : a conventional DAPT (c-DAPT) group treated with aspirin and clopidogrel (n=89), and an individualized DAPT (i-DAPT) group (n=98) where antiplatelet regimens were adjusted based on preoperative platelet reactivity measured by VerifyNow. The primary outcome was the incidence of ischemic lesions on diffusion-weighted imaging (DWI) following CAS. Risk factors and the impact of DAPT personalization on ischemic changes were analyzed using multivariate logistic regression.
resultsDWI-positive ischemic lesions were observed in 62.9% of the c-DAPT group and 51% of the i-DAPT group (p=0.07). Although the difference was not statistically significant, there was a trend toward reduced ischemic changes with individualized therapy. Multivariate analysis identified hypertension, diabetes mellitus, and unstable plaque as independent predictors of post-CAS ischemic changes. Subgroup analysis showed that VerifyNow-guided i-DAPT significantly reduced ischemic events in patients with unstable plaques (odds ratio, 0.49; p=0.03), whereas no significant effect was observed in other subgroups.
conclusionVerifyNow-guided personalization of antiplatelet therapy is a safe and may have the potential to reduce periprocedural ischemic complications in CAS, particularly in patients with unstable plaques. Further multicenter prospective studies are needed to validate these findings and optimize individualized antiplatelet regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.